MALIGNANT MELANOMA

This study tested a new drug (SAR444245) combined with an immunotherapy (cemiplimab) in 46 people with advanced melanoma or skin squamous cell carcinoma that could not be removed by surgery. The goal was to see if the combination shrank tumors. The trial was terminated early, so …

This study tested an experimental drug called vobramitamab duocarmazine in people with advanced prostate cancer that no longer responds to hormone therapy, as well as other solid tumors like melanoma and lung cancer. The goal was to see if the drug could shrink tumors or slow dis…

This early-phase study tested an experimental oral drug called IK-595 in 75 adults with advanced solid tumors (like colorectal, pancreatic, or lung cancer) that have specific RAS or RAF gene mutations and no standard treatment options left. The goal was to check the drug's safety…

This early-stage study tested a new drug called PF-08046037, given alone or with another drug (sasanlimab), in people with advanced lung, head and neck, melanoma, or pancreatic cancers. The goal was to check safety and how the body processes the drug. Only 8 people took part befo…

This early-phase study tested a new drug, PF-07284890, alone or with another drug, in people with advanced solid tumors (like melanoma or lung cancer) that have a specific BRAF V600 gene change, including those that spread to the brain. The main goals were to check safety, how th…

This study tested a new drug called PF-08046031 in 11 adults with advanced melanoma or other solid tumors that had spread or had no standard treatment. The goal was to check the drug's safety and side effects. The study was stopped early, so results are limited.